BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 16279795)

  • 1. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
    J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
    Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
    J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Lazzari P; Ruiu S; Sanna A; Loriga G; Manca I; Falzoi M; Dessì C; Curzu MM; Chelucci G; Pani L; Pinna GA
    J Med Chem; 2006 Dec; 49(25):7502-12. PubMed ID: 17149879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
    Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
    J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
    J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
    Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
    Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
    Showalter VM; Compton DR; Martin BR; Abood ME
    J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives.
    Lazzari P; Distinto R; Manca I; Baillie G; Murineddu G; Pira M; Falzoi M; Sani M; Morales P; Ross R; Zanda M; Jagerovic N; Pinna GA
    Eur J Med Chem; 2016 Oct; 121():194-208. PubMed ID: 27240274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.
    Silvestri R; Cascio MG; La Regina G; Piscitelli F; Lavecchia A; Brizzi A; Pasquini S; Botta M; Novellino E; Di Marzo V; Corelli F
    J Med Chem; 2008 Mar; 51(6):1560-76. PubMed ID: 18293908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.
    Pinna G; Loriga G; Lazzari P; Ruiu S; Falzoi M; Frau S; Pau A; Murineddu G; Asproni B; Pinna GA
    Eur J Med Chem; 2014 Jul; 82():281-92. PubMed ID: 24922543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor.
    Deng H; Gifford AN; Zvonok AM; Cui G; Li X; Fan P; Deschamps JR; Flippen-Anderson JL; Gatley SJ; Makriyannis A
    J Med Chem; 2005 Oct; 48(20):6386-92. PubMed ID: 16190764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist.
    Hung MS; Chang CP; Li TC; Yeh TK; Song JS; Lin Y; Wu CH; Kuo PC; Amancha PK; Wong YC; Hsiao WC; Chao YS; Shia KS
    ChemMedChem; 2010 Sep; 5(9):1439-43. PubMed ID: 20652930
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
    Lange JH; Coolen HK; van Stuivenberg HH; Dijksman JA; Herremans AH; Ronken E; Keizer HG; Tipker K; McCreary AC; Veerman W; Wals HC; Stork B; Verveer PC; den Hartog AP; de Jong NM; Adolfs TJ; Hoogendoorn J; Kruse CG
    J Med Chem; 2004 Jan; 47(3):627-43. PubMed ID: 14736243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentacycle derivatives as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Lee SH; Ahn K; Lee M; Han HK; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6632-6. PubMed ID: 19850473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.
    Rinaldi-Carmona M; Barth F; Congy C; Martinez S; Oustric D; Pério A; Poncelet M; Maruani J; Arnone M; Finance O; Soubrié P; Le Fur G
    J Pharmacol Exp Ther; 2004 Sep; 310(3):905-14. PubMed ID: 15131245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.
    Deiana V; Gómez-Cañas M; Pazos MR; Fernández-Ruiz J; Asproni B; Cichero E; Fossa P; Muñoz E; Deligia F; Murineddu G; García-Arencibia M; Pinna GA
    Eur J Med Chem; 2016 Apr; 112():66-80. PubMed ID: 26890113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.
    Hurst D; Umejiego U; Lynch D; Seltzman H; Hyatt S; Roche M; McAllister S; Fleischer D; Kapur A; Abood M; Shi S; Jones J; Lewis D; Reggio P
    J Med Chem; 2006 Oct; 49(20):5969-87. PubMed ID: 17004712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
    Manera C; Benetti V; Castelli MP; Cavallini T; Lazzarotti S; Pibiri F; Saccomanni G; Tuccinardi T; Vannacci A; Martinelli A; Ferrarini PL
    J Med Chem; 2006 Oct; 49(20):5947-57. PubMed ID: 17004710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.